

<p>BSE Limited 1st Floor, P J Towers, Dalal Street, <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra – Kurla Complex, Bandra [East], <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
Date: January 17, 2019	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated January 17, 2019 titled “Zydus final approval from the USFDA for Acetazolamide ER Capsules”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Acetazolamide ER Capsules

Ahmedabad, 17 January, 2019

Zydus Cadila has received the final approval from the USFDA to market Acetazolamide ER Capsules (US RLD – Diamox). It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Acetazolamide is a potent carbonic anhydrase inhibitor. Acetazolamide ER capsules are used to treat certain types of glaucoma (caused by increased ocular pressure) and to treat or prevent altitude sickness (acute mountain sickness).

The group now has 246 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
